The FDA has approved a combination therapy for muscle-invasive bladder cancer. This treatment involves pembrolizumab, or pembrolizumab with berahyaluronidase alfa-pmph, each combined with enfortumab vedotin-ejfv.
Key points
• The FDA approved a new treatment for muscle-invasive bladder cancer.
• The approved therapy combines pembrolizumab, or a variant with berahyaluronidase alfa-pmph, with enfortumab vedotin-ejfv.
• This provides additional options for patients with this cancer type.
Sources
- FDA Drugs Resource - FDA drug information resource
- Clinical Trial Details - Information on a relevant clinical trial
Corporate Update - Financial Reporting
Tempus AI will report its second-quarter financial results for the period ending June 30, 2026. The company will host a conference call and live audio webcast to discuss these results and provide a business update.
Key points
• Tempus AI will release Q2 2026 financial results on July 30, 2026.
• The report will cover the quarter ended June 30, 2026.
• Founder and CEO Eric Lefkofsky will lead the conference call and business update.
Corporate Culture - Intern Q&A Session
Truveta recently held its annual Ask Me Anything session, providing interns an opportunity to interact with CEO Terry Myerson. The discussion covered topics such as career development, leadership, innovation, and Truveta's mission.
Key points
• Truveta hosted an annual Ask Me Anything event for its interns.
• Interns engaged with CEO Terry Myerson.
• Discussion topics included career advice, leadership, innovation, and Truveta's mission.
Sources
Industry Event - Healthcare Conference Presence
Commure will participate in HIC 2026 in Sydney, Australia, from August 3–4. Specialists from enterprise sales, clinical strategy, engineering, and partnerships will be present at Booth 39.
Key points
• Commure will attend the HIC 2026 conference in Sydney.
• The event runs from August 3–4.
• Their team at Booth 39 includes specialists from various departments.
Sources
- Commure Events - Event information page
Oncology - NSCLC Treatment Discussion
A discussion at ASCO MOS 2026 in Kuala Lumpur focused on the evolving role of perioperative immunochemotherapy in Non-Small Cell Lung Cancer (NSCLC). Establishing more evidence for neoadjuvant and perioperative treatments requires multidisciplinary case discussions.
Key points
• The role of perioperative immunochemotherapy in NSCLC was discussed at ASCO MOS 2026.
• Evidence for neoadjuvant and perioperative treatments is still gathering.
• Multidisciplinary discussions are important for reviewing treatment cases.
Sources
Oncology - ALK+ NSCLC Treatment
Results from the ELEVATE phase 3 trial for adjuvant ensartinib in completely resected ALK+ Non-Small Cell Lung Cancer (NSCLC) have been published. The study reports disease-free survival rates and adverse event profiles.
Key points
• Adjuvant ensartinib in ALK+ NSCLC showed a 24-month DFS of 86.4% versus 53.5% for stage II–IIIB.
• The overall population saw 87.3% versus 57.2% 24-month DFS.
• The hazard ratio for DFS was 0.20 in both groups.
• Grade ≥3 adverse events occurred in 35.8% of patients, primarily rash.
Sources
- NEJM Article - Publication outlet for the trial results
AI in Healthcare - Nursing Workflow Tools
AmbienceAI has introduced a Nursing Suite designed for inpatient nurses. This suite incorporates AI for shift preparation, chart reasoning, and ambient flowsheet documentation, co-designed with frontline nursing staff.
Key points
• AmbienceAI launched a Nursing Suite for inpatient nurses.
• The suite offers AI-powered shift preparation and real-time chart reasoning.
• Ambient flowsheet documentation is included in the new tools.
• The system was co-designed with nurses and validated in clinical settings.
Sources
Healthcare Operations - Revenue Cycle Optimization
An analysis suggests the healthcare revenue cycle faces structural issues, with many current solutions addressing secondary problems. The proposed fix involves embedding coding intelligence directly into the point of care.
Key points
• The healthcare revenue cycle has a structural problem, not just operational issues.
• Many existing industry solutions target the wrong aspects of the problem.
• A proposed solution involves integrating coding intelligence at the point of patient care.
Sources
- Forbes Article - Publication source for the analysis
Industry Trends - Healthcare Breakthroughs
A publication reviews significant healthcare developments that occurred during the first half of 2026. This content highlights key stories from the year to date.
Key points
• A new publication summarizes top healthcare stories from H1 2026.
• The content focuses on breakthroughs from the first six months of the year.
Sources
- Breaking Ground Substack - Source for the breakthrough summary
Oncology - Advanced NSCLC Treatment
A new meta-analysis explores the benefits of first-line chemoimmunotherapy compared to IO monotherapy for patients with advanced Non-Small Cell Lung Cancer (NSCLC) who have high PD-L1 expression (≥50%). The analysis suggests chemoimmunotherapy may offer a greater overall survival benefit.
Key points
• A meta-analysis compares first-line chemoimmunotherapy and IO monotherapy in advanced NSCLC.
• The study focuses on patients with high PD-L1 expression (≥50%).
• Chemoimmunotherapy may provide a better overall survival benefit in this patient group.
Sources
- ASCO Post Article - Publication detailing the findings
